An Introduction to Thoracic Oncology
Although the incidence and mortality from lung cancer is decreasing in some Western countries due to decades of public education and tobacco control policies, it remains a major cause of mortality worldwide. The treatment landscape for non-small-cell lung cancer (NSCLC) has been transformed in the past decade, thanks to the development of immune checkpoint inhibitors targeting the programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), and therapies targeting specific genetic alterations.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever changing landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities
Our supporting partners do not constitute an endorsement of the content on this page.
Thoracic Oncology Content
Current and future considerations for the use of immune checkpoint inhibitors in non-small cell lung cancer
A leading expert discusses the current landscape and future perspectives of immune checkpoint inhibitors for the treatment of NSCLC
- Discuss the clinical implications for the latest data for immunotherapies in early-stage NSCLC
- Evaluate the use of novel agents in combination with immunotherapy in NSCLC using the latest evidence
- Describe how current and emerging biomarkers may guide immunotherapy treatment selection in NSCLC
Continuing the momentum in SCLC: Exploring second-line and novel therapy options
MDT specialists discuss the current and emerging second-line treatment options for patients with extensive-stage small cell lung cancer (ES-SCLC)
- Describe the current and emerging second-line treatment options for patients with SCLC
- Identify patient- and disease-related factors that affect treatment decisions for patients with SCLC in the second-line setting
- Describe strategies to manage adverse events for patients with SCLC in the second-line treatment setting
Advancing the multidisciplinary management of rare and unusual NETs: Integrating new approaches to treatment and care
Watch leading specialists involved in the multidisciplinary care of patients with rare and unusual neuroendocrine tumours discuss new and emerging approaches for diagnosis and treatment.
- Recognize the role of the MDT in addressing diagnostic and treatment challenges associated with rare and unusual neuroendocrine tumours (NETs)
- Evaluate the factors guiding treatment selection and clinical management decisions in rare and unusual NETs
- Appraise the efficacy and safety of new and emerging treatment options for rare and unusual NETs
E-cigarette or Vaping Product-associated Lung Injury in the Time of Coronavirus Disease 2019: A Review
touchREVIEWS in Respiratory & Pulmonary Diseases. 2022;7(1):25–9
Electronic nicotine delivery systems, colloquially referred to as e-cigarettes (ECs), or vaping products were introduced in the US market in 2007 as an alternative to cigarette smoking. They were marketed as a better alternative to nicotine replacement therapy for stopping cigarette smoking, as ECs are considered less harmful than tobacco cigarette smoking.1 These findings have been […]
Biomarker-guided management of NSCLC: Current and future strategies
Select a discussion in the hub to watch our multidisciplinary faculty share their insights on biomarker testing methods and interpretation of results to guide treatment selection for a patient with advanced NSCLC.
- Discuss current recommendations for biomarker testing in patients with advanced NSCLC
- Identify the most appropriate biomarker testing methods for each patient with advanced NSCLC
- Use biomarker testing results to select appropriate targeted and immuno-oncological treatment options for patients with advanced NSCLC
Evidence and E-cigarettes – The English Perspective
European Respiratory & Pulmonary Diseases. 2019;5(1):10–11
Recently, there has been much media coverage on the topic of e-cigarettes. Approaches to new data suggesting that e-cigarettes may be harmful have differed between countries. In particular, the attitude of public health bodies in England has differed significantly from those in other countries internationally. American electronic cigarette company Juul has been accused of deliberately […]
Advanced Lung Imaging – Magnetic Resonance Imaging and Artificial Intelligence
While advances in radiotracers are increasing the utility of computed tomography (CT) and positron emission tomography (PET) in the imaging of lung disease, these techniques have limitations. Magnetic resonance imaging (MRI) is considered the most useful imaging modality in radiology, due to its ability to provide three-dimensional clear images, high spatial resolution and high contrast, […]
Lung Cancer – the Latest in Imaging
Lung cancer is the most commonly diagnosed cancer, accounting for 11.6% of all cases, and the leading cause of cancer death (18.4% of all cancer deaths).1 It is classified as non-small cell lung cancer (NSCLC), which accounts for 85–90% of all lung cancers, small-cell lung cancer (SCLC), and neuroendocrine tumours (NET).2 For all subtypes, early […]
The Use of Sweetened and Flavored Electronic Cigarettes Among Young People—a Growing Concern
US Respiratory & Pulmonary Diseases. 2019;4(1):12–13
Q. How prevalent is the use of electronic cigarettes in children and adolescents? Based on the 2017 National Youth Survey published by the US Food and Drug Administration, 2.1 million American middle and high school students had used e-cigs in the past 30 days.1 E-cig use has surpassed the use of conventional tobacco cigarettes in […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!